Product
Therapeutic Area
Phase 1
Phase 2
Phase 3
BLA/NDA

Hematology

Essential Thrombocythemia

Immunotherapy: Breast & Gastric Cancer

Node-positive or node negative/triple negative, HER2 IHC 1+/2+
2b
High risk, node-positive or negative, HER2 IHC 3+
Ductal Carcinoma in Situ (DCIS)
VADIS
Gastric, HER2 IHC 1+/2+/3+

Immunotherapy: Gynecological Cancer

Ovarian & Endometrial
Ovarian & Breast
Completed
Planned
Ongoing

Hematology

Therapeutic Area:
Essential Thrombocythemia
Phase 1
Phase 2
Phase 3
BLA/NDA

Immunotherapy: Breast & Gastric Cancer

Therapeutic Area:
Node-positive or node negative/triple negative, HER2 IHC 1+/2+
Phase 1
Phase 2
Phase 3
BLA/NDA
2b
Therapeutic Area:
High risk, node-positive or negative, HER2 IHC 3+
Phase 1
Phase 2
Phase 3
BLA/NDA
Product
NeuVax™
Therapeutic Area:
Ductal Carcinoma in Situ (DCIS)
Phase 1
Phase 2
Phase 3
BLA/NDA
VADIS
Product
NeuVax™
Therapeutic Area:
Gastric, HER2 IHC 1+/2+/3+
Phase 1
Phase 2
Phase 3
BLA/NDA

Immunotherapy: Gynecological Cancer

Product
GALE-301
Therapeutic Area:
Ovarian & Endometrial
Phase 1
Phase 2
Phase 3
BLA/NDA
Therapeutic Area:
Ovarian & Breast
Phase 1
Phase 2
Phase 3
BLA/NDA
Completed
Planned
Ongoing

NeuVax™ is an investigational product. Efficacy has not been established. Trastuzumab is a product of Genentech.